

EB Research Partnership, Inc. and Affiliate

Consolidated Financial Statements
and Supplementary Information

December 31, 2020

EB Research Partnership, Inc. and Afilliate

Table of Contents
December 31, 2020

	<u>Page</u>
Independent Auditors' Report	1
Consolidated Financial Statements	
Consolidated Statement of Financial Position	3
Consolidated Statement of Activities and Changes in Net Assets	4
Consolidated Statement of Cash Flows	5
Consolidated Statement of Functional Expenses	6
Notes to Consolidated Financial Statements	7
Supplementary Information	
Consolidating Statement of Financial Position	14
Consolidating Statement of Activities and Changes in Net Assets	15

Independent Auditors' Report

To the Board of Directors of
EB Research Partnership, Inc. and Affiliate

Report on the Consolidated Financial Statements

We have audited the accompanying consolidated financial statements of EB Research Partnership, Inc. and Affiliate which comprise the consolidated statement of financial position as of December 31, 2020, and the related consolidated statements of activities and changes in net assets, cash flows and functional expenses for the year then ended, and the related notes to the consolidated financial statements.

Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditors' judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of EB Research Partnership, Inc. and Affiliate as of December 31, 2020, and the changes in their consolidated net assets and their consolidated cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America.

Other Matters

Report on Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The consolidating information on pages 14 and 15 is presented for purposes of additional analysis of the consolidated financial statements rather than to present the financial position and changes in net assets of the individual organizations, and it is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Baker Tilly US, LLP

New York, New York
June 22, 2021

EB Research Partnership, Inc. and Affiliate

Consolidated Statement of Financial Position

December 31, 2020

Assets

Current Assets

Cash and cash equivalents	\$ 9,119,089
Contributions receivable	1,553,666
Other assets	105,835

Total current assets 10,778,590

Long-Term Assets

Investments	4,609,359
Contributions receivable, net	1,051,012
Fixed assets, net	11,783
Trademarks	15,231

Total long-term assets 5,687,385

Total assets \$ 16,465,975

Liabilities and Net Assets

Current Liabilities

Accounts payable and accrued expenses	\$ 68,100
Grants payable	1,600,143
Other liabilities	13,574

Total current liabilities 1,681,817

Commitments and Contingencies

Net Assets

Net assets without donor restrictions:	
Undesignated	10,291,480
Board designated	2,000,000

Total net assets without donor restrictions 12,291,480

Net assets with donor restrictions 2,492,678

Total net assets 14,784,158

Total liabilities and net assets \$ 16,465,975

See notes to consolidated financial statements

EB Research Partnership, Inc. and Affiliate

Consolidated Statement of Activities and Changes in Net Assets

Year Ended December 31, 2020

	Without Donor Restrictions	With Donor Restrictions	Total
Support and Revenue			
Contributions	\$ 1,912,456	\$ 349,870	\$ 2,262,326
Fundraising events	2,619,271	-	2,619,271
Less direct expenses of fundraising events	(184,319)	-	(184,319)
Investment income, net	29,063	-	29,063
In-kind contributions	866,959	-	866,959
Net assets released from donor restrictions	1,231,054	(1,231,054)	-
	<u>6,474,484</u>	<u>(881,184)</u>	<u>5,593,300</u>
Expenses			
Program and research	3,703,472	-	3,703,472
Management and general	1,211,441	-	1,211,441
Fundraising	677,574	-	677,574
	<u>5,592,487</u>	<u>-</u>	<u>5,592,487</u>
Changes in net assets before other item and income related to acquisition	881,997	(881,184)	813
Other Item			
Foreign currency translation gain	15,880	-	15,880
Changes in net assets before income related to acquisition	897,877	(881,184)	16,693
Inherent contribution	135,222	-	135,222
Changes in net assets	1,033,099	(881,184)	151,915
Net Assets, Beginning	<u>11,258,381</u>	<u>3,373,862</u>	<u>14,632,243</u>
Net Assets, Ending	<u>\$ 12,291,480</u>	<u>\$ 2,492,678</u>	<u>\$ 14,784,158</u>

See notes to consolidated financial statements

EB Research Partnership, Inc. and Affiliate

Consolidated Statement of Cash Flows

Year Ended December 31, 2020

Cash Flows From Operating Activities

Changes in net assets	\$ 151,915
Adjustments to reconcile changes in net assets to net cash flows from operating activities:	
Inherent contribution	(135,222)
Amortization of fixed assets	2,357
Change in amortization of pledge receivable discount	(32,750)
Bad debt	60,000
Changes in operating assets and liabilities:	
Contributions receivable	1,034,433
Other assets	(63,228)
Accounts payable and accrued expenses	22,898
Grants payable	166,703
Other liabilities	2,087
	<hr/>
Net cash flows from operating activities	1,209,193

Cash Flows From Investing Activities

Cash acquired in acquisition	138,080
Purchase of investments	(414,227)
Sale of investments	34,838
Purchase of fixed assets	(14,140)
	<hr/>
Net cash flows from investing activities	(255,449)

Net change in cash and cash equivalents 953,744

Cash and Cash Equivalents, Beginning

8,165,345

Cash and Cash Equivalents, Ending

\$ 9,119,089

See notes to consolidated financial statements

EB Research Partnership, Inc. and Affiliate

Consolidated Statement of Functional Expenses

Year Ended December 31, 2020

	Program and Research	Management and General	Fundraising	Total
Grants	\$ 3,328,999	\$ -	\$ -	\$ 3,328,999
Salaries and benefits	81,821	49,264	450,095	581,180
Payroll taxes	5,249	3,562	24,472	33,283
Professional fees	103,388	199,918	22,116	325,422
Office expense	169,198	25,067	75,390	269,655
Bad debt	-	60,000	-	60,000
Payment processor fees	-	-	30,992	30,992
Information technology	-	-	33,502	33,502
Insurance	-	3,720	743	4,463
Travel	3,902	597	1,857	6,356
Meetings	1,269	2,037	8,516	11,822
Occupancy	5,646	4,317	29,891	39,854
Subtotal	3,699,472	348,482	677,574	4,725,528
Donated professional fees	4,000	862,959	-	866,959
Total expenses	<u>\$ 3,703,472</u>	<u>\$ 1,211,441</u>	<u>\$ 677,574</u>	<u>\$ 5,592,487</u>

See notes to consolidated financial statements

EB Research Partnership, Inc. and Affiliate

Notes to Consolidated Financial Statements

December 31, 2020

1. Organization and Nature of Activities

EB Research Partnership, Inc. (EBRP) is a New York not-for-profit corporation. EBRP's mission is curing and treating Epidermolysis Bullosa (EB) a devastating and rare genetic disease. All funds raised go towards funding research to cure EB. EBRP provides research funding to accelerate research focused on curing and treating EB.

EBRP holds fundraisers in the forms of local events, receptions and an annual gala, Action for Jackson. EBRP also raises funds via online contributions and participation in various charitable athletic events such as marathons and half-marathons.

EBRP employs a venture philanthropy model with all of its research grant making. EBRP retains legal and beneficial rights to intellectual property developed under certain research grants and will share in that revenue stream when the investment becomes commercially viable.

In 2020, EBRP, based in New York, and EB Research Partnership (Australia) Limited (EBRPAL) have united to become the largest global organization focused on funding research to discover treatments and cures for EB.

As the two leading organizations funding EB research across the globe, EBRP and EBRPAL have formalized their funding partnership in 2020, which began in 2018, with EBRPAL coming under the EBRP banner as "EB Research Partnership Australia." They will leverage EBRP's competitive grant approval process, renowned Scientific Advisory Board, and innovative venture philanthropy business model to compound the impact of research funds. Together, the organizations will work around the clock to propel life-saving therapies into the hands of patients and families.

Effective July 1, 2020 (the Acquisition Date), EBRP became the sole member of EBRPAL in a strategic affiliation which would allow both EBRP and EBRPAL to better achieve their missions by leveraging resources, achieving efficiencies in operations and benefit from synergies between programs. See Note 3 for further details.

2. Summary of Significant Accounting Policies

Principles of Consolidation

The accompanying consolidated financial statements include the accounts of EBRP and EBRPAL (collectively, the Organization). All intercompany account balances and transactions have been eliminated in consolidation.

Basis of Presentation

The consolidated financial statements of the Organization have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP).

The net assets of the Organization are classified and reported as follows:

Net Assets Without Donor Restrictions - Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objectives of the Organization. Board-designated net assets include net assets without donor restrictions that have been designated by the board for specific purposes.

Net Assets With Donor Restrictions - Net assets subject to stipulations imposed by donors. Some donor restrictions are temporary in nature: those restrictions will be met by actions of the Organization or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the funds be maintained in perpetuity.

EB Research Partnership, Inc. and Affiliate

Notes to Consolidated Financial Statements

December 31, 2020

Donor restricted contributions are reported as increases in net assets with donor restrictions. When a restriction expires, net assets are reclassified from net assets with donor restrictions to net assets without donor restrictions in the consolidated statement of activities and changes in net assets.

Revenue Recognition

All contributions are considered available for the Organization's general programs unless specifically restricted by the donor. Contributions including unconditional promises to give (pledges) are recognized as revenues in the period received. Conditional promises to give contain donor-imposed conditions that represent a barrier that must be overcome as well as a right of release from obligation and are recognized when they become unconditional, that is, when the conditions on which they depend are substantially met.

Donor-Imposed Restrictions

The Organization reports gifts of cash and other assets as assets with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. Donor restricted contributions whose restrictions are met in the same reporting period are reported as net assets without donor restrictions. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statement of activities and changes in net assets as net assets released from donor restrictions.

The Organization reports gifts of land, buildings and equipment as support without donor restrictions unless explicit donor stipulations specify how the donated assets must be used. Gifts of long-lived assets with explicit restrictions that specify how the assets are to be used and gifts of cash or other assets that must be used to acquire long-lived assets are reported as donor restricted support. Absent explicit donor stipulations about how long those long-lived assets must be maintained, the Organization reports expirations of donor restrictions when the donated or acquired long-lived assets are placed in service.

Contributions Receivable

Unconditional promises to give by donors (contributions receivable) are recorded at net realizable value if expected to be collected in one year. Unconditional promises to give that are expected to be collected in future years are recorded at the present value of their estimated future cash flows. The discounts on those amounts are computed using a risk adjusted discount rate applicable to the year in which the promises are received. Amortization of the discounts is included in contribution revenue.

In-Kind Contributions and Contributed Services

The Organization recognizes the fair value of in-kind contributions and contributed services received if such services (a) create or enhance nonfinancial assets or (b) require specialized skills that are provided by individuals possessing those skills and would typically need to be purchased if not contributed. The Organization receives services from a large number of volunteers who give significant amounts of their time to the Organization's programs and fundraising campaigns but do not meet the criteria for financial statement recognition.

Income Tax Status

EBRP is exempt from federal and state income tax under the provisions of Section 501(c)(3) of the Internal Revenue Code; therefore, no provision for income taxes has been made in these consolidated financial statements. The Organization has also been classified as a public charity within the meaning of Section 509(a) and qualifies for deductible contributions as provided in Section 170(b)(1)(A)(vi).

EB Research Partnership, Inc. and Affiliate

Notes to Consolidated Financial Statements

December 31, 2020

EBRPAL is a company limited by guarantee, incorporated and domiciled in Australia. No provision for income tax has been raised as EBRPAL is exempt from income tax in Australia under Division 50 of the *Income Tax Assessment Act 1997*.

Uncertain Tax Positions

Management evaluated the Organization's tax positions and concluded that the Organization has not taken any uncertain tax positions that would require adjustment to the consolidated financial statements to comply with the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) No. 740.

Cash and Cash Equivalents

The Organization considers all highly liquid investments with maturities of three months or less, when purchased, to be cash equivalents. The Organization maintains its cash with a high quality financial institution.

Investments

Investments includes marketable securities in private company stock and equity securities without readily determinable fair values. Investments in marketable securities are recorded on the trade date and are carried at fair value. Realized and unrealized gains and losses are included in the investment income (loss) on the consolidated statement of activities and changes in net assets. Investment income (loss) is reported net of investment expenses. Investments acquired by gift are recorded at their fair values at the date of the gift.

In accordance with the FASB Accounting Standards Update (ASU) 2016-01, *Recognition and Measurement of Financial Assets and Financial Liabilities*, equity securities without readily determinable fair value are recorded at their cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. As of each reporting period (December 31st), the Organization performs a qualitative assessment considering impairment indicators to evaluate whether these investments are impaired. For the year ended December 31, 2020, no impairment loss is deemed necessary.

Fixed Assets, Net

Office furniture, equipment and software are carried at cost if purchased, or if acquired in in-kind, at their fair value at the date of the gift. Any expenditure over \$1,000 individually, in these categories is capitalized. Fixed assets are depreciated using the straight-line basis over the following estimated useful lives:

	<u>Years</u>
Office equipment	5
Software	3
Computers and equipment	3

Costs incurred for repairs and maintenance are charged to expense as incurred.

Fair Value

Fair value refers to the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants in the market in which the entity transacts. The Organization must determine whether its assets and liabilities recorded at fair value were based on Level 1 (valued based on quoted prices in an active market for identical assets and liabilities), Level 2 (valued based on observable market based inputs or unobservable inputs that are corroborated by market data) or Level 3 (valued based on unobservable inputs that are not corroborated by market data) measurements within the fair value hierarchy.

EB Research Partnership, Inc. and Affiliate

Notes to Consolidated Financial Statements

December 31, 2020

Research Grants and Grants Payable

The Organization awards medical/scientific grants. Grants payable represent unconditional obligations of the Organization to provide funds in connection with research grant agreements.

Functional Allocation of Expenses

The costs of providing the various programs and other activities have been summarized on a functional basis in the consolidated statements of activities and changes in net assets and functional expenses. Accordingly, salaries and benefits, a portion of office expense, and occupancy have been allocated among the programs and supporting services benefited. Salary and benefits are allocated based on time and effort. A portion of office expense and occupancy have been allocated based on full time equivalency. The remaining expenses are directly charged.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements. They also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Foreign Currency Translation

The assets and liabilities of EBRPAL, which are stated in Australian dollars, are translated to U.S. dollars (USD) using the exchange rate in effect at the date of the consolidated statement of financial position. Revenues, expenses, gains and losses are translated using the average exchange rate for the year. Gains or losses on foreign currency translation are recognized in the accompanying consolidated financial statements.

Allowance for Doubtful Accounts

Management must make estimates of the uncollectability of contributions receivable. Management considers past payment experience and historical trends when assessing the adequacy of allowance for doubtful accounts. Allowance for doubtful accounts is not considered necessary as of December 31, 2020.

Measure of Operations

The Organization uses an operating measure that includes all operating revenues and expenses that are an integral part of its programs and supporting activities to support operating expenditures. The measure of operations excludes foreign currency translation gain defined as an other item and inherent contribution.

Recent Accounting Pronouncement

In September 2020, the FASB issued ASU 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*. The ASU is intended to improve transparency in the reporting of contributed nonfinancial assets, also known as gifts-in-kind, for not-for-profit organizations. The amendments in this ASU should be applied on a retrospective basis and are effective for annual periods beginning after June 15, 2021. Early adoption is permitted. Management is currently evaluating the impact of ASU 2020-07 on the consolidated financial statements.

EB Research Partnership, Inc. and Affiliate

Notes to Consolidated Financial Statements

December 31, 2020

3. Business Combination

Effective July 1, 2020 (the Acquisition Date), EBRP became the sole member of EBRPAL in a strategic affiliation which would allow both EBRP and EBRPAL to better achieve their missions by leveraging resources, achieving efficiencies in operations and benefit from synergies between programs. There was no consideration transferred for this transaction and the transaction costs were absorbed by EBRP. The Organization accounted for the business combination by applying the acquisition method and, accordingly, the inherent contribution is valued as the excess of the fair value of the assets acquired over the fair value of the liabilities assumed. The Organization has reflected the acquisition accounting of EBRPAL's balances in the accompanying consolidated financial statements as of July 1, 2020.

The results of EBRPAL's operations have been included in the consolidated financial statements since July 1, 2020. The estimated fair value of the amounts recognized for the assets acquired and liabilities assumed on the Acquisition Date are as follows:

Assets:	
Cash and cash equivalents	\$ 138,080
Receivables	690
Other assets	<u>10,739</u>
Total assets	<u>149,509</u>
Liabilities:	
Accounts payable	2,800
Other liabilities	<u>11,487</u>
Total liabilities	<u>14,287</u>
Net assets (inherent contribution) as of Acquisition Date	<u>\$ 135,222</u>

4. Contributions Receivable

Contributions receivable are reported at fair value using a risk adjusted discount rate that is appropriate for the expected collection period. The discount rate for pledges due within two to five years ranged from 0.13 percent to 1.58 percent. Contributions receivable, net, are summarized as follows as of December 31, 2020:

Amounts due in:	
One year or less	\$ 1,553,666
Two to five years	<u>1,066,667</u>
Gross contributions receivable	2,620,333
Less present value adjustment	<u>15,655</u>
Contributions receivable, net	<u>\$ 2,604,678</u>

EB Research Partnership, Inc. and Affiliate

Notes to Consolidated Financial Statements

December 31, 2020

5. Investments

A summary of investments held is as follows as of December 31, 2020:

Marketable securities:	
Private company stock	\$ 38,882
Equity securities without readily determinable fair values (a)	<u>4,570,477</u>
 Total	 <u>\$ 4,609,359</u>

(a) Investments in equity securities without readily determinable fair values represent programmatic investments, which consist of preferred stock in four privately held companies with voting rights ranging approximately 5 percent - 38 percent. The Organization does not have the ability to exercise significant influence over operating and financial policies of these companies.

Fair Value Hierarchy

Accounting guidance requires disclosures about assets and liabilities carried at fair value and defines fair value as the prices that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). It also establishes a hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The guidance describes three levels of inputs that may be used to measure fair value.

Valuation Techniques and Inputs

For the private company stock, the fair value has been estimated using the market approach under the precedent transaction method by considering the sale price of shares in a recent financing.

Assets measured at fair value on a recurring basis are summarized below as of December 31, 2020:

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Marketable securities:				
Stocks	\$ -	\$ 38,882	\$ -	\$ 38,882

6. Grants Payable

The Organization awards grants to research institutions to find treatments and a cure for EB. Grants awarded but unpaid were approximately \$1,600,000 as of December 31, 2020.

7. Board Designated Net Assets

The following represents the composition of board-designated net assets as of December 31, 2020:

Board designated for philanthropic investments	\$ 2,000,000
--	--------------

8. Net Assets With Donor Restrictions

The following items are included in net assets with donor restrictions as of December 31, 2020:

Donor stipulated purposes:	
Time restriction	\$ 2,492,678

EB Research Partnership, Inc. and Affiliate

Notes to Consolidated Financial Statements

December 31, 2020

Net assets were released from donor restrictions by satisfying the restricted purposes as follows for the year ended December 31, 2020:

Time restriction	\$ 1,231,054
------------------	--------------

9. In-Kind Contributions and Contributed Services

The Organization benefited from in-kind contributions for the year ended December 31, 2020. The amount has been reported as both in-kind revenue and in-kind expense in the consolidated financial statements. The value of such services for the year ended December 31, 2020 is as follows:

Professional fees	\$ 866,959
-------------------	------------

10. Concentrations

The Organization has cash balances in financial institutions in excess of amounts that are federally insured. The uninsured balances totaled approximately \$8,708,000 as of December 31, 2020. The Organization maintains its cash with high quality financial institutions which EBRP believes limits these risks.

As of December 31, 2020, approximately 76 percent of total contributions receivable was due from one donor, which is also a board member.

For the year ended December 31, 2020, approximately 31 percent of total revenues was from 2 separate board member donors, with each representing greater than 10 percent of total revenues.

11. Liquidity and Availability of Resources

The following represents the Organization's financial assets available for general expenditures within one year as of December 31, 2020. Financial assets are considered unavailable when illiquid or not convertible to cash within one year.

Cash and cash equivalents	\$ 9,119,089
Contributions receivable	<u>1,553,666</u>
	10,672,755
Less board-designated net assets included above	<u>2,000,000</u>
Total financial assets available to meet cash needs for general expenditures within one year	<u>\$ 8,672,755</u>

The Organization's policy is to maintain \$1,150,000 of financial assets available within a ninety-day period of time.

12. Subsequent Events

Management has evaluated subsequent events through June 22, 2021, which is the date the consolidated financial statements were available to be issued. There were no subsequent events that require disclosure.

EB Research Partnership, Inc. and Affiliate

Consolidating Statement of Financial Position

December 31, 2020

	EB Research Partnership, Inc.	EB Research Partnership (Australia) Limited	Eliminations	Consolidated Total
Assets				
Current Assets				
Cash and cash equivalents	\$ 8,958,367	\$ 160,722	\$ -	\$ 9,119,089
Contributions receivable	1,553,666	-	-	1,553,666
Other assets	102,363	3,472	-	105,835
Total current assets	<u>10,614,396</u>	<u>164,194</u>	<u>-</u>	<u>10,778,590</u>
Long-Term Assets				
Investments	4,609,359	-	-	4,609,359
Contributions receivable, net	1,051,012	-	-	1,051,012
Fixed assets, net	11,783	-	-	11,783
Trademarks	15,231	-	-	15,231
Interest in net assets of affiliate	146,150	-	(146,150)	-
Total long-term assets	<u>5,833,535</u>	<u>-</u>	<u>(146,150)</u>	<u>5,687,385</u>
Total assets	<u>\$ 16,447,931</u>	<u>\$ 164,194</u>	<u>\$ (146,150)</u>	<u>\$ 16,465,975</u>
Liabilities and Net Assets				
Current Liabilities				
Accounts payable and accrued expenses	\$ 63,630	\$ 4,470	\$ -	\$ 68,100
Grants payable	1,600,143	-	-	1,600,143
Other liabilities	-	13,574	-	13,574
Total current liabilities	<u>1,663,773</u>	<u>18,044</u>	<u>-</u>	<u>1,681,817</u>
Commitments and Contingencies				
Net Assets				
Net assets without donor restrictions:				
Undesignated	10,291,480	146,150	(146,150)	10,291,480
Board designated	2,000,000	-	-	2,000,000
Total net assets without donor restrictions	<u>12,291,480</u>	<u>146,150</u>	<u>(146,150)</u>	<u>12,291,480</u>
Net assets with donor restrictions	<u>2,492,678</u>	<u>-</u>	<u>-</u>	<u>2,492,678</u>
Total net assets	<u>14,784,158</u>	<u>146,150</u>	<u>(146,150)</u>	<u>14,784,158</u>
Total liabilities and net assets	<u>\$ 16,447,931</u>	<u>\$ 164,194</u>	<u>\$ (146,150)</u>	<u>\$ 16,465,975</u>

EB Research Partnership, Inc. and Affiliate

Consolidating Statement of Activities and Changes in Net Assets

Year Ended December 31, 2020

	January 1, 2020 Through December 31, 2020			July 1, 2020 Through December 31, 2020			Total Before Eliminations	Eliminations	Consolidated Total
	EB Research Partnership, Inc.			EB Research Partnership (Australia) Limited					
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total			
Support and Revenue									
Contributions	\$ 1,862,775	\$ 349,870	\$ 2,212,645	\$ 49,681	\$ -	\$ 49,681	\$ 2,262,326	\$ -	\$ 2,262,326
Fundraising events	2,615,990	-	2,615,990	3,281	-	3,281	2,619,271	-	2,619,271
Less direct expenses of fundraising events	(183,090)	-	(183,090)	(1,229)	-	(1,229)	(184,319)	-	(184,319)
Investment income, net	29,032	-	29,032	31	-	31	29,063	-	29,063
In-kind contributions	866,959	-	866,959	-	-	-	866,959	-	866,959
Earnings of affiliate	10,928	-	10,928	-	-	-	10,928	(10,928)	-
Net assets released from donor restrictions	1,231,054	(1,231,054)	-	-	-	-	-	-	-
Total support and revenue	6,433,648	(881,184)	5,552,464	51,764	-	51,764	5,604,228	(10,928)	5,593,300
Expenses									
Program and research	3,703,472	-	3,703,472	-	-	-	3,703,472	-	3,703,472
Management and general	1,211,441	-	1,211,441	-	-	-	1,211,441	-	1,211,441
Fundraising	620,858	-	620,858	56,716	-	56,716	677,574	-	677,574
Total expenses	5,535,771	-	5,535,771	56,716	-	56,716	5,592,487	-	5,592,487
Changes in net assets before other item and income related to acquisition	897,877	(881,184)	16,693	(4,952)	-	(4,952)	11,741	(10,928)	813
Other Item									
Foreign currency translation gain	-	-	-	15,880	-	15,880	15,880	-	15,880
Changes in net assets before income related to acquisition	897,877	(881,184)	16,693	10,928	-	10,928	27,621	(10,928)	16,693
Inherent contribution	135,222	-	135,222	-	-	-	135,222	-	135,222
Changes in net assets	1,033,099	(881,184)	151,915	10,928	-	10,928	162,843	(10,928)	151,915
Net Assets, Beginning	11,258,381	3,373,862	14,632,243	135,222	-	135,222	14,767,465	(135,222)	14,632,243
Net Assets, Ending	\$ 12,291,480	\$ 2,492,678	\$ 14,784,158	\$ 146,150	\$ -	\$ 146,150	\$ 14,930,308	\$ (146,150)	\$ 14,784,158